Alginate/chitosan Microcapsules for In-Situ Delivery of the Protein, Interleukin-1 Receptor Antagonist (Il-1Ra), for the Treatment of Dextran Sulfate Sodium (Dss)-Induced Colitis in a Mouse Model.

Cao Jin,Cheng Jin,Xi Siyu,Qi Xueyong,Shen Song,Ge Yanru
DOI: https://doi.org/10.1016/j.ejpb.2019.02.011
IF: 5.589
2019-01-01
European Journal of Pharmaceutics and Biopharmaceutics
Abstract:Targeted delivery of bioactive compounds such as proteins to the colon has numerous advantages for the therapeutic treatment of inflammatory bowel disease. The present study sought to fabricate alginate/chitosan microcapsules containing IL-1Ra (Alg/Chi/IL-1Ra MC) via a single-step electrospraying method. Two important factors of efficacy were measured-the pH-responsiveness of the microcapsule and the in-vitro drug release profile. The DSS-induced colitis mouse model was used to evaluate the therapeutic effect of the Alg/Chi/IL-1Ra microcapsules, with results showing the protective effect of the Alg/Chi microcapsules for the passage of IL-1Ra through the harsh environment of the upper gastrointestinal tract. This effect was owing to the pH-sensitive response of the microcapsule, which allowed the targeted release of IL-1Ra in the colon. DAI evaluation, colon length, colon tissue morphology, histologic damage scores and relative protein concentrations (MPO, TNF-α and IL-1β) demonstrated that the Alg/Chi/IL-1Ra microcapsules alleviated DSS-induced colitis in mice. The present study thus demonstrates a practical means of oral delivery of proteins, in-situ colon release, and a promising application of IL-1Ra in the treatment of autoimmune and inflammatory diseases.
What problem does this paper attempt to address?